Modulators of complement activation: a patent review (2008 – 2013)

Bibliography

• Emlen W, Li W, Kirschfink M. Therapeutic complement inhibition: new developments. Semin Thromb Hemost 2010;36:660-8
   PubMed Web of Science ®Google Scholar
• Dodds AW, Matsushita M. The phylogeny of the complement system and the origins of the classical pathway. Immunobiology 2007;212:233-43
   PubMed Web of Science ®Google Scholar
• Mastellos D, Andronis C, Persidis A, Lambris JD. Novel biological networks modulated by complement. Clin Immunol 2005;115:225-35
   PubMed Web of Science ®Google Scholar
• Sarma JV, Ward PA. The complement System. Cell Tissue Res 2011;343:227-35
   PubMed Web of Science ®Google Scholar
• Doni A, Garlanda C, Bottazzi B, et al. Interactions of the humoral pattern recognition molecule PTX3 with the complement system. Immunobiology 2012;217:1122-8
   PubMed Web of Science ®Google Scholar
• Ali YM, Kenawy HI, Muhammad A, et al. Human L-ficolin, a recognition molecule of the lectin activation pathway of complement, activates complement by binding to pneumolysin, the major toxin of streptococcus pneumoniae. PLoS One 2013;8:e0082583
   Web of Science ®Google Scholar
• Thrane AS, Skehan JD, Thrane PS. A novel interpretation of immune redundancy and duality in reperfusion injury with important implications for intervention in ischaemic disease. Med Hypotheses 2007;68:1363-70
   PubMed Web of Science ®Google Scholar
• van der Pol P, Schlagwein N, van Gijlswijk DJ, et al. Mannan-binding lectin mediates renal ischemia/reperfusion injury independent of complement activation. Am J Transplant 2012;12:877-87
   PubMed Web of Science ®Google Scholar
• Leinhase I, Rozanski M, Harhausen D, et al. Inhibition of the alternative complement activation pathway in traumatic brain injury by a monoclonal anti-factor B antibody: a randomized placebo-controlled study in mice. J Neuroinflammation 2007;4:13
   PubMed Web of Science ®Google Scholar
• Bexborn F, Andersson PO, Chen H, et al. The tick-over theory revisited: formation and regulation of the soluble alternative complement C3 convertase (C3(H(2)O)Bb). Mol Immunol 2008;45:2370-9
   PubMed Web of Science ®Google Scholar
• Hourcade DE. The role of properdin in the assembly of the alternative pathway of C3 convertases of complement. J Biol Chem 2006;281:2128-32
   PubMed Web of Science ®Google Scholar
• Alcorlo M, Tortajada A, Rodríguez de Córdoba S, et al. Structural basis for the stabilization of the complement alternative pathway C3 convertase by properdin. Proc Natl Acad Sci USA 2013;110:13504-9
   PubMed Web of Science ®Google Scholar
• Harboe M, Mollnes TE. The alternative complement pathway revisited. J Cell Mol Med 2008;12:1074-84
   PubMed Web of Science ®Google Scholar
• Rawal N, Rajagopalan R, Salvi VP. Activation of complement component C5: comparison of C5 convertases of the lectin pathway and classical pathway of complement. J Biol Chem 2008;283:7853-63
   PubMed Web of Science ®Google Scholar
• Pangburn MK, Rawal N. Structure and function of complement C5 convertase enzymes. Biochem Soc Trans 2002;30:1006-10
   Google Scholar
• Zipfel PF, Skerka C. Complement regulators and inhibitory proteins. Nat Rev Immunol 2009;9:1-12
   Web of Science ®Google Scholar
• Rambach G, Würzner R, Speth C. Complement: an efficient sword of innate immunity. Contrib Microbiol 2008;15:78-100
   PubMedGoogle Scholar
• Larghi EL, Kaufman TS. Isolation, synthesis and complement inhibiting activity of the naturally occurring K-76, its analogues and derivatives. ARKIVOC 2011;vii:49-102
   Google Scholar
• Rawal N, Rajagopalan R, Salvi VP. Stringent regulation of complement lectin pathway C3/C5 convertase by C4b-binding protein (C4BP). Mol Immunol 2009;46:2902-10
   PubMed Web of Science ®Google Scholar
• Frank MM. Complement disorders and hereditary angioedema. J Allergy Clin Immunol 2010;125:S262-71
   PubMed Web of Science ®Google Scholar
• Truedsson L, Bengtsson AA, Sturfelt G. Complement deficiencies and systemic lupus erythematosus. Autoimmunity 2007;40:560-6
   PubMed Web of Science ®Google Scholar
• Chen M, Daha MR, Kallenberg CG. The complement system in systemic autoimmune disease. J Autoimmun 2010;34:J276-86
   PubMed Web of Science ®Google Scholar
• Füst A, Csuka D, Imre L, et al. The role of complement activation in the pathogenesis of Fuchs' dystrophy. Mol Immunol 2014;58:177-81
   PubMed Web of Science ®Google Scholar
• Ballanti E, Perricone C, Greco E, et al. Complement and autoimmunity. Immunol Res 2013;56:477-91
   PubMed Web of Science ®Google Scholar
• Gorbet MB, Sefton MV. Biomaterial-associated thrombosis: roles of coagulation factors, complement, platelets and leukocytes. Biomaterials 2004;25:5681-703
   PubMed Web of Science ®Google Scholar
• Noris M, Remuzzi G. Overview of complement activation and regulation. Semin Nephrol 2013;33:479-92
   PubMed Web of Science ®Google Scholar
• Holers VM. The spectrum of complement alternative pathway-mediated diseases. Immunol Rev 2008;223:300-16
   PubMed Web of Science ®Google Scholar
• Craig TJ, Rojavin MA, Machnig T, et al. Effect of time to treatment on response to C1 esterase inhibitor concentrate for hereditary angioedema attacks. Ann Allergy Asthma Immunol 2013;111:211-15
   PubMed Web of Science ®Google Scholar
• Subasinghe NL, Khalil E, Travins JM, et al. Design and synthesis of polyethylene glycol-modified biphenylsulfonyl-thiophene-carboxamidine inhibitors of the complement component C1s. Bioorg Med Chem Lett 2012;22:5303-7
   PubMed Web of Science ®Google Scholar
• Sonkar GK, Usha SRG. Study on the role of humoral immunity in renal transplant rejections and its correlation with histopathological findings. Saudi J Kidney Dis Transpl 2011;22:901-10
   PubMedGoogle Scholar
• Chen G, Chen S, Chen X. Role of complement and perspectives for intervention in transplantation. Immunobiology 2013;218:817-27
   PubMed Web of Science ®Google Scholar
• Langlois PF, Gawryl MS. Complement activation occurs through both classical and alternative pathways prior to onset and resolution of adult respiratory distress syndrome. Clin Immunol Immunopathol 1988;47:152-63
   PubMedGoogle Scholar
• Spirig R, Gajanayake T, Korsgren O, et al. Low molecular weight dextran sulfate as complement inhibitor and cytoprotectant in solid organ and islet transplantation. Mol Immunol 2008;45:4084-94
   PubMed Web of Science ®Google Scholar
• Imai N, Nishi S, Alchi B. Immunohistochemical evidence of activated lectin pathway in kidney allografts with peritubular capillary C4d deposition. Nephrol Dial Transplant 2006;21:2589-95
   PubMed Web of Science ®Google Scholar
• Farrar CA, Asgari E, Schwaeble W, et al. Which pathways trigger the role of complement in ischaemia/reperfusion injury? Front Immunol 2012;3:341
   PubMed Web of Science ®Google Scholar
• Burwick RM, Fichorova RN, Dawood HY, et al. Urinary excretion of C5b-9 in severe preeclampsia: tipping the balance of complement activation in pregnancy. Hypertension 2013;62:1040-5
   PubMed Web of Science ®Google Scholar
• Sacks S, Karegli J, Farrar CA, et al. Targeting complement at the time of transplantation. Adv Exp Med Biol 2013;735:247-55
   PubMed Web of Science ®Google Scholar
• Schwertz H, Carter JM, Russ M, et al. Serine protease inhibitor nafamostat given before reperfusion reduces inflammatory myocardial injury by complement and neutrophil inhibition. J Cardiovasc Pharmacol 2008;52:151-60
   PubMed Web of Science ®Google Scholar
• Pedroni SM, Gonzalez JM, Wade J, et al. Complement inhibition and statins prevent fetal brain cortical abnormalities in a mouse model of preterm birth. Biochim Biophys Acta 2014;1842:107-15
   PubMed Web of Science ®Google Scholar
• Murata K, Baldwin WM III. Mechanisms of complement activation, C4d deposition, and their contribution to the pathogenesis of antibody-mediated rejection. Transplantat Rev (Orlando) 2009;23:139-50
   PubMedGoogle Scholar
• Frangogiannis NG. The immune system and cardiac repair. Pharmacol Res 2008;58:88-111
   PubMed Web of Science ®Google Scholar
• Lambris JD. Current topics in complement II. Springer, New York; 2008
   Google Scholar
• Arumugam TV, Woodruff TM, Lathia JD, et al. Neuroprotection in stroke by complement inhibition and immunoglobulin therapy. Neuroscience 2009;158:1074-89
   PubMed Web of Science ®Google Scholar
• Holers MV. The complement system as a therapeutic target in autoimmunity. Clin Immunol 2003;107:140-51
   PubMed Web of Science ®Google Scholar
• van Werkhoven MB, Damman J, van Dijk MC, et al. Complement mediated renal inflammation induced by donor brain death: role of renal C5a-C5aR interaction. Am J Transplant 2013;13:875-82
   PubMed Web of Science ®Google Scholar
• Varga L, Farkas H. rhC1INH: a new drug for the treatment of attacks in hereditary angioedema caused by C1-inhibitor deficiency. Expert Rev Clin Immunol 2011;7:143-53
   PubMed Web of Science ®Google Scholar
• Gál P, Dobó J, Beinrohr L, et al. Inhibition of the serine proteases of the complement system. Adv Exp Med Biol 2013;735:23-40
   PubMed Web of Science ®Google Scholar
• Yang K, DeAngelis RA, Reed JE, et al. Complement in action: an analysis of patent trends from 1976 through 2011. Adv Exp Med Biol 2013;734:301-13
   Google Scholar
• Munro HS. Treatment of inflammation and the complement and kinin cascades in a patient, particularly in chronic ulcerous skin lesions. US143478; 2010
   Google Scholar
• Shepard AR, Clark AF, Klimko PG, Wax MB. Complement C1q inhibitors for the prevention and treatment of glaucoma. US117098; 2009
   Google Scholar
• Christadoss P, Tuzun E. Methods and materials for treating autoimmune diseases and conditions. US7923010; 2011
   Google Scholar
• Ali F, Gushue J, Meegalla S, et al. Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions. MY137509; 2009. US234081; 2005
   Google Scholar
• Subasinghe NL, Ballentine S, Travins JM, et al. Thiophene sulfoximines, compositions thereof, and methods of treating complement-mediated diseases and conditions. US7868023; 2011
   Google Scholar
• Nalin S, Ehab K, Farah A, et al. Conjugated complement cascade inhibitors. MY138732; 2009. US004031; 2005
   Google Scholar
• Fung MSC, Sun CRY, Sun WNC. Complement inhibitors and uses thereof. US8221756; 2012
   Google Scholar
• Kotwal GJ, Arason GJ. Methods for treatment or prophylaxis of atherosclerosis and reperfusion injury. US200645; 2008
   Google Scholar
• Garred P, Glue HT, Skjodt M-O. MASP isoforms as inhibitors of complement activation. US282285; 2012
   Google Scholar
• Garred P, Glue TH. Therapeutic targeting of ficolin-3. WO000471; 2013
   Google Scholar
• Stahl GL. Methods and compositions for the regulation of LCP (LCP)-associated complement activation in hyperglycemic myocardial damage. US293524; 2011
   Google Scholar
• Gal P, Zavodszky P, Ambrus-Aikelin G. Folded recombinant catalytic fragments of multidomain serine proteases, preparation and uses thereof. US042248; 2009
   Google Scholar
• Krishna NK, Cunnion K. Methods for regulating complement cascade proteins using astrovirus coat protein and derivatives thereof. US058972; 2013. US055106; 2010
   Google Scholar
• Krishna NK, Cunnion KM. Peptide compounds to regulate the complement system. US244924; 2013
   Google Scholar
• Fung SC. Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury. US0017031; 2009
   Google Scholar
• Jensenius JC, Thiel S. MASP 2, a complement-fixing enzyme and uses for it. US8551790; 2013
   Google Scholar
• Willis AC, Schwaeble H-W, Stover CM. MASP-2, a complement fixing enzyme, and uses for it. US219965; 2012
   Google Scholar
• Dudler T, Gombotz WR, Brian J, et al. Compositions for inhibiting MASP-2 dependent complement activation. US282263; 2012
   Google Scholar
• Schwaeble H-W, Stover CM, Tedford CE, et al. Methods for treating conditions associated with MASP-2 dependent complement activation. US258095; 2012
   Google Scholar
• Demopulos GA, Schwaeble H-W, Tedford CE, Parent JB. Methods for treating conditions associated with MASP-2 dependent complement activation. US266559; 2013
   Google Scholar
• Demopulos GA, Dudler T, Schwaeble H-W. Methods for treating conditions associated with MASP-2 dependent complement activation. US266560; 2013
   Google Scholar
• Proudfoot A, Antonsson B, Kontula L, et al. Use of an immunoglobulin domain-containing cell surface recognition molecule for treating diseases. US193414; 2008
   Google Scholar
• Schwaeble H-W, Demopulos GA. Compositions and methods of inhibiting MASP-1 and/or MASP-3 for the treatment of paroxysmal nocturnal hemoglobinuria. WO180834; 2013
   Google Scholar
• O'brien G, Pike RN, Dean MM, et al. Mannose binding lectin and uses thereof. NZ535600; 2008. WO090774; 2003
   Google Scholar
• Rekha B. Methods and compositions of inhibiting complement and cellular activation with dextran sulfate. US087393; 2010
   Google Scholar
• Chen D, Zhang T, Zhang Y. Plant polysaccharide and preparation method and use thereof. CN101390868; 2009
   Google Scholar
• Fung MSC, Sun WNC, Sun CRY. Anti-factor D antibodies and methods of treatment. US8124090; 2012
   Google Scholar
• An LL, Fung C, Kelley RF, et al. Methods of treating with anti factor D antibodies. US8187604; 2012
   Google Scholar
• Hass P, Jianping Y, Katschke K Jr, et al. Prevention and treatment of complement-associated eye conditions. US0302333; 2013
   Google Scholar
• Fung MSC, Yao Z. Use of complement pathway inhibitors to treat ocular diseases. US214538; 2009
   Google Scholar
• Huang AJ, Kelley RF, Lowman H, et al. Humanized anti-factor D antibodies and uses thereof. SG189756; 2009. US269338; 2009
   Google Scholar
• An LL, Fung SC, Kelley RF, et al. Humanized anti-factor D antibodies and uses thereof. AU200988; 2013. US171070; 2013
   Google Scholar
• Altmann E, Hommel U, Lorthiois ELJ, et al. Complement pathway modulators and uses thereof. US295884; 2012
   Google Scholar
• Romano C. Treatment of age-related macular degeneration using inhibitors of complement factor D. US269318; 2008
   Google Scholar
• Rekha B. Anti-properdin antibodies. US8435512; 2013
   Google Scholar
• Holers VM, Thurman JM, Tomlinson S, Stahel PF. Method for using inhibition of ACP in formulation for treatment of traumatic brain injury, spinal cord injury. JP162543; 2012. US292141; 2006
   Google Scholar
• Song W. Anti-properdin antibodies and uses thereof. WO006449; 2013
   Google Scholar
• Fung SC, Yao Z. Use of complement pathway inhibitors to treat ocular diseases. AU200223; 2013
   Google Scholar
• Juo SH, Chou W-W, Wu JM, Liang CL. Method of modulating complement factor B (CFB) expression in cells. US245108; 2012
   Google Scholar
• Adams CM, Babu C, Capparelli MP, et al. Complement Pathway modulators and uses thereof. US296377; 2013
   Google Scholar
• Chen C, Kaleko M, Li B, et al. Complement factor B analogs and their uses. CA2833931; 2012
   Google Scholar
• Van Lookeren Campagne M, Deforge L. Anti-factor B antibodies and their uses. US230997; 2012
   Google Scholar
• Holers VM, Thurman JM, Taube C, et al. lnhibition of factor B, the ACP and methods related thereto. EP2340850; 2011
   Google Scholar
• Emlen W, Holers VM, Flynn P. Humaneered anti-factor B antibody. US7964705; 2011
   Google Scholar
• Rekha B. Method of inhibiting complement activation with factor Bb specific antibodies. US239573; 2010
   Google Scholar
• Rekha B. Method of inhibiting complement activation with factor Ba specific antibodies and use thereof. US015139; 2010
   Google Scholar
• Bansal R. Humanized and chimeric anti-factor bb antibodies and uses thereof. WO152020; 2013
   Google Scholar
• Taylor RP, Dilillo DJ, Lindorfer MA, Pawluczkowycz AW. Compositions and methods for regulating the ACP of complement. US004183; 2009
   Google Scholar
• Kolln J, Spillner E, Bredehorst R. Complement depletion using recombinant human C-3 derivatives. US270324; 2009
   Google Scholar
• Vogel C-W, Fritzinger DC. Human complement C3 derivates with cobra venom factor-like function. US234191; 2008
   Google Scholar
• Rooijakkers SHM, Van Wamel WJB, Van Kessel CPM, Van Strijp JAG. Therapeutic use of SCIN, a staphylococcal complement inhibitor in inflammatory diseases. US246175; 2009
   Google Scholar
• Lambris JD, Geisbrecht BV. Secreted Staphylococcus aureus proteins and peptides for use in inhibiting activation of the complement system. US046075; 2011
   Google Scholar
• De Silva A, Tyson K, Fikrig E. Ixodes scapularis salivary proteins and methods of use for modulation of the alternative complement pathway. US014218; 2011
   Google Scholar
• McGeer PL, Lee M, Guo J-P, et al. Selective inhibition of the membrane attack complex of complement and C3 convertase by low molecular weight components of the aurin tricarboxylic acid synthetic complex. US035392; 2013
   Google Scholar
• Lambris JD, Janssen B, Gros P. Structure of compstatin-C3 complex and use for rational drug design. WO153963; 2008
   Google Scholar
• Lambris JD, Taylor FB, Lupu F, Kinasewitz G. Treatment of sepsis using complement inhibitors. US053302; 2013
   Google Scholar
• Lambris JD, Taylor FB, Lupu F, et al. Treatment of sepsis using complement inhibitors. WO106635; 2011
   Google Scholar
• Francois C, Deschatelets P. Methods of treating chronic disorders with complement inhibitors. WO178083; 2012
   Google Scholar
• Francois C, Deschatelets P, Olson P. Local complement inhibition for treatment of complement-mediated disorders. US8580735; 2013
   Google Scholar
• Francois C, Deschatelets P, Olson P. Compositions and methods for treatment of trauma. WO015087; 2009
   Google Scholar
• Francois C, Deschatelets P. Compstatin analogs for treatment of rhinosinusitis and nasal polyposis. US324482; 2013
   Google Scholar
• Pecht I, Erdei A, Eitan A. Complement C3a derived dimeric peptides and uses thereof. US306561; 2011
   Google Scholar
• Bansal R. Humanized and chimeric anti-factor C3 antibodies and uses thereof. WO152024; 2013
   Google Scholar
• Bansal R. Method of inhibiting complement activation with human anti-factor C3 antibodies and use thereof. US288493; 2012
   Google Scholar
• Lambris JD, Schmidt C, Ricklin D. Regulator of complement activation and uses thereof. WO142362; 2013
   Google Scholar
• Ashkenazi A, Fong S, Goddard A, et al. Treatment of complement-associated disorders. US0189626; 2012
   Google Scholar
• Shi H, Millis AJT, Nishikawa K, Mallik PK. Aptamer modulators of complement protein C3 and biologically active proteolytic products thereof. US141382; 2012
   Google Scholar
• Etemad-Gilbertson B, Guild BC, Kim Y-I, et al. Compositions and methods for antibodies targeting complement protein C3b. US291106; 2010
   Google Scholar
• Van Lookeren Campagne M. C3b antibodies and methods for the prevention and treatment of complement-associated disorders. US128674; 2012
   Google Scholar
• Holers VM, Thurman JM, Kulik L. Antibodies to the C3d fragment of complement component 3. US129728; 2013
   Google Scholar
• Bansal R. Method of inhibiting complement activation with human anti-factor C3 antibodies and use thereof. US288493; 2012
   Google Scholar
• Lambris JD, Rafail S. Wound healing using complement inhibitors. WO174055; 2012
   Google Scholar
• Lambris JD, Nadeau J, Doerner S, Berger NA. Treatment of colon cancer using complement inhibitors. WO135624; 2012
   Google Scholar
• Lambris JD, Sander CE. Complement inhibitors for treatment of injury form intracerebral hemorrhage. US256136; 2011
   Google Scholar
• Lambris JD, Ritis K. Method of inhibiting biomaterial-induced procoagulant activity using complement inhibitors. US8445190; 2013
   Google Scholar
• Heinrich H-W. Immuno-Adsorbers for treatment of inflammations. US255344; 2008
   Google Scholar
• Bell L, Rother RP. Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement. AU206214; 2013. US237515; 2012
   Google Scholar
• Gies D, Hunter JW, Springhorn JP. Polypeptides that bind to human complement component C5. US273052; 2013
   Google Scholar
• Rother RP, Wang H, Zhong Z. Prolongation of survival of an allograft by inhibiting complement activity. AU200641; 2013
   Google Scholar
• Diefenbach-Streiber B, Eberth A, Guild BC, et al. Compositions and methods for antibodies targeting complement protein C5. US064836; 2013
   Google Scholar
• Roguska M, Keating MT, Guild BC, et al. Antigens and uses thereof. US166748; 2010
   Google Scholar
• Yi W. Method of treating of asthma using antibody to complement component C5. JP215674; 2010
   Google Scholar
• Evans MJ, Matis L, Mueller E, et al. Anti-C5 antibodies and their therapeutic uses. EP2270047; 2011
   Google Scholar
• Rother RP, Halstead S, Willison H. Method and compositions for the treatment of antibody mediated neuropathies. US143343; 2010
   Google Scholar
• Rother RP, Wang H, Lao A. Prolongation of survival of an allograft by inhibiting complement activity. US028850; 2009
   Google Scholar
• Fung M, Lu M, Sun WNC. Complement pathway inhibitors binding to C5 and. C5a without preventing the formation of C5b. US230522; 2013
   Google Scholar
• Fung MSC, Sun C, Sun BNC. Inhibition of complement C5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection. PT1325033; 2010. US041875; 2002
   Google Scholar
• Rother RP, Bedrosian C, Squinto SP, Bell L. Methods and compositions for treating complement-associated disorders. US225056; 2012
   Google Scholar
• Magro C. Methods and compositions for treating Degos' disease. US0064820; 2013. MX010116; 2012
   Google Scholar
• Berghard C, Berglund M, Stromberg P, et al. Polypeptides binding to human complement C5. WO126006; 2013
   Google Scholar
• Francois C, Deschatelets P, Olson P. Modulation and repletion/replacement of the complement system for treatment of trauma. US190221; 2011
   Google Scholar
• Nunn MA. Complement inhibitors. US263482; 2011
   Google Scholar
• Nunn MA, Lea SM, Roversi P. Modified OMCI as a complement inhibitor. US115773; 2012
   Google Scholar
• Hamer J, Weston-Davies W. Method of treating myasthenia gravis. US209459; 2009
   Google Scholar
• Hamer J. Method of treating respiratory disorders. US105611; 2010
   Google Scholar
• Hamer J. Method of treating peripheral nerve disorders. US111929; 2010
   Google Scholar
• Epstein D, Kurz JC. Complement binding aptamers and anti-C5 agents useful in the treatment of ocular disorders. AU204622; 2013. JP067661; 2013
   Google Scholar
• Benedict C, Epstein D, Wilson C, et al. Aptamer therapeutics useful in the treatment of complement-related disorders. US0237589; 2013
   Google Scholar
• Wang Y. Mutated Fc monoclonal antibodies specific to C5, C5 convertase, C5a or C5b-9 which do not activate complement cascade for use in treatment of pulmonary conditions. NZ563509; 2010. US027160; 2005
   Google Scholar
• Tamburini PP. Bispecific antibodies that bind to complement proteins. US002931; 2011
   Google Scholar
• Baas F, Fluiter K. Complement antagonists and uses thereof. US171176; 2011
   Google Scholar
• Kirsch WM, Crofton A, Freeman T, et al. Substances and methods for the treatment of cerebral amyloid angiopathy related conditions or diseases. WO138368; 2013
   Google Scholar
• Smith RJH, Zhang Y, Marsh HC. Treatment of chronic nephropathies using soluble complement receptor type 1 (SCR1). US071413; 2012
   Google Scholar
• Seelen MA. Method of improving transplant function using soluble complement receptor type 1 (SCRl). US232020; 2012
   Google Scholar
• Lake P, Mullon C. Immunosuppressive combination and its use in the treatment or prophylaxis of insulin-producing cell graft rejection. US236382; 2011
   Google Scholar
• Chen X, Holers VM. Three-dimensional structure of complement receptor type 2 and uses thereof. US266571; 2013
   Google Scholar
• Kovacs JM, Hannan JP, Holers VM. Complement receptor 2 (CR2) targeting groups. US190477; 2013
   Google Scholar
• Tomlinson S, Holers VM. Complement receptor 1 and 2 fusion proteins. US8540997; 2013
   Google Scholar
• Robinson WH, Holers VM, Rozelle AL. Complement inhibitory agents as therapeutics in post-traumatic and degenerative arthritis. US324585; 2009
   Google Scholar
• Gilkeson G, Tomlinson S, Holers VM, Rohrer B. Targeting complement factor H for treatment of diseases. US015127; 2011. US221011; 2008
   Google Scholar
• Holers VM, Ristano AM. Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis. US029912; 2013
   Google Scholar
• Würzner R, Lesiak-Markowicz I. CAHGTIP inhibitors for use in the treatment of candidiasis. WO017691; 2013
   Google Scholar
• Yang C. Modulation of complement system activation for treatment of bleeding-related inflammation. US092493; 2010
   Google Scholar
• Lambris JD, Markiewski MM. Complement inhibitors as therapeutic agents for treatment of cancer. US044983; 2011
   Google Scholar
• Lambris JD, Ignatius A, Huber-Lang M. Promotion of fracture healing using complement inhibitors. WO162215; 2012
   Google Scholar
• Fan P, Greenman KL, Leleti MR, et al. C5aR antagonists. US0317028; 2013
   Google Scholar
• Zipfel P, Skerka C, Wallich R. Novel regulators of the innate immune system. US236455; 2011
   Google Scholar
• Atkinson JP, Hourcade D, Krych M. Modified truncated complement system regulators. US119400; 2008
   Google Scholar
• Medof EM, Kuttner-Kondo L. Hybrid and chimeric polypeptides that regulate activation of complement. US226020; 2012
   Google Scholar
• Garred P, Glue TH, Skjodt MO. Chimeric inhibitor molecules of complement activation. US217616; 2013
   Google Scholar
• Baas F, Ramaglia V. Complement inhibition for improved nerve regeneration. US143344; 2010
   Google Scholar
• Kumar-Singh R, Cashman SM, Sweigard JH. Compositions, methods and kits for modeling, diagnosing, and treating complement disorders. US149373; 2013
   Google Scholar
• Kumar-Singh R, Cashman SM, Ramo K. Compositions, kits and methods for treatment of complement-related disorders. US143953; 2013
   Google Scholar
• Li Z, Song S, Xu Z, et al. Fusion protein of antibody targeted complement regulatory factor for treating myasthenia gravis. CN102115499; 2011
   Google Scholar
• Song H, Zhang C, Jia L, et al. Novel targeted fusion protein with anti-inflammatory action and use thereof. CN101475644; 2011
   Google Scholar
• Song H, Zhang C, Jia L, et al. Antibody targeted complement inhibitor with anti-inflammatory action. CN101602809; 2009
   Google Scholar
• Gronski P, Licht C, Hoppe B, et al. Factor H for the treatment of chronic nephropathies and production thereof. US046062; 2011
   Google Scholar
• Hageman GS. Therapeutic compositions for age-related macular degeneration comprising a complement factor H with isoleucine at residue 62 and tyrosine at residue 402. US8497350; 2013
   Google Scholar
• Lambris JD. Factor H binding peptides and uses thereof. WO087925; 2012. EP2655400; 2013
   Google Scholar
• Heinen S, Lambris JD, Lauer N, et al. Potent inhibitors of complement activation. WO095519; 2012
   Google Scholar
• Lachmann P. Treatment of diseases related to hyperactivity of the complement system. US087905; 2012
   Google Scholar
• Chen D, Jin J. Shikonin compound and purpose thereof in preparing anti-Complement medicines. CN103083292; 2013
   Google Scholar
• Chen D, Jin J. Boraginaceae phenol compound and purpose thereof in preparing anti-Complement medicines. CN103087020; 2013
   Google Scholar
• Chen D, Jin J, Li G. Shikonin tetramer compound and purpose thereof in pharmacy. CN103086864; 2013
   Google Scholar
• Chen D, Jin J. Alkannin dimer compounds and uses of the same in drug preparation. CN103086863; 2013
   Google Scholar
• Chen D, Jin J. Application of flavan compound in preparing anti-Complement medicines. CN103083342; 2013
   Google Scholar
• Sun L, Xi Z, Sun L, et al. Acylated flavonoid glycoside compounds and application thereof in preparation of complement inhibitor medicines. CN102304158; 2012
   Google Scholar
• Chen D, He C. Application of formononetin in preparation of anti-Complement medicines. CN102100691; 2011
   Google Scholar
• Chen D, Fu L, Liu R. Phenolic acid compound and use thereof in the preparation of anti-Complementary medicaments. CN101817746; 2010
   Google Scholar
• Allegretti A, Moriconi A, Aramini A, et al. (R)-Arylalkylamino derivatives and pharmaceutical compositions containing them. US124664; 2009
   Google Scholar
• Moriconi A, Aramini A. (R)-4-(Heteroaryl) phenylethyl derivatives and pharmaceutical compositions containing them. US249198; 2010
   Google Scholar
• Woodruff TM, Taylor SM. Treatment of neurological conditions using complement C5a receptor modulators. US227492; 2009
   Google Scholar
• Levdanskij VA, Levdanskij AV, Sokolenko VA, et al. Method of obtaining betulin 3,28-disulfate. RU2468031; 2011
   Google Scholar
• Levdanskij VA, Levdanskij AV. Method of obtaining betulin 3,28-disulfate. RU2461561; 2011
   Google Scholar
• Levdanskij VA, Levdanskij AV, Kuznetsov BN. Method of producing sodium salt of 3-sulphate betulinic acid. RU2479588; 2012
   Google Scholar
• Levdanskij VA, Levdanskij AV. Method for preparing betulinic acid 3-sulphate disodium salt. RU2482123; 2012
   Google Scholar
• Larghi EL, Operto MA, Torres R, Kaufman TS. Compuestos inhibidores del complemento, sus sales y derivados farmacéuticamente aceptables, procedimientos para su preparación y composiciones farmacéuticas que los comprenden. AR0101056; 2012
   Google Scholar
• Larghi EL, Operto MA, Torres R, Kaufman TS. Synthesis and classical pathway complement inhibitory activity of C7-functionalized filifolinol derivatives, inspired in K-76 COOH. Eur J Med Chem 2012;55:74-84
   PubMed Web of Science ®Google Scholar
• Larghi EL, Operto MA, Torres R, Kaufman TS. New inhibitors of the complement system inspired in K76-COOH. A SAR study of filifolinol derivatives through modifications of the C3' position. Bioorg Med Chem Lett 2009;19:6172-5
   PubMedGoogle Scholar
• Useglio M, Castellano PM, Operto MA, et al. Synthesis and complement inhibitory activity of 3H-spiro[benzofuran-2,1'-cyclohexanes] derived from the naturally-occurring filifolinol. Bioorg Med Chem Lett 2006;16:5097-101
   PubMed Web of Science ®Google Scholar
• Bradbury BJ, Bartyzel P, Kaufman TS, et al. Synthesis and complement inhibitory activity of B/C/D/-ring analogues of the fungal metabolite 6,7-diformyl-3',4',4a',5', 6',7',8',8a'-octahydro-4,6',7'-trihydroxy-2',5',8a'-tetramethylspiro[1'(2'H)-naphthalene-2(3H)-benzofuran]. J Med Chem 2003;46:2697-705
   PubMed Web of Science ®Google Scholar
• Kaufman TS, Srivastava RP, Sindelar RD, et al. Design, synthesis, and evaluation of A/C/D-ring analogs of the fungal metabolite K-76 as potential complement inhibitors. J Med Chem 1995;38:1437-45
   PubMed Web of Science ®Google Scholar
• Patil G. Hydroxylamine compounds and methods of their use. EP2620429; 2008
   Google Scholar